Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of repeated subcutaneous BIM23B065 in acromegaly
2015-003868-37Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Aug 2016
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BIM23B065 in acromegaly, sponsored by Ipsen. Primary endpoint: Growth hormone response at Day 14. Started Aug 2016; status: terminated.
02
Drugs
BIM23B065
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2015-003868-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003868-37.